Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Hims & Hers Health (HIMS)
Analysts are pulling back from the Healthcare sector as 2 experts expressed today bearish sentiments on Myriad Genetics (MYGN – Research Report) and Hims & Hers Health (HIMS – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Myriad Genetics (MYGN)
In a report released yesterday, Michael Ryskin from Bank of America Securities reiterated a Sell rating on Myriad Genetics, with a price target of $4.00. The company’s shares closed last Monday at $4.38.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
Myriad Genetics has an analyst consensus of Hold, with a price target consensus of $6.33, a 48.2% upside from current levels. In a report released today, TipRanks – Anthropic also downgraded the stock to Sell with a $4.00 price target.
See today’s best-performing stocks on TipRanks >>
Hims & Hers Health (HIMS)
In a report released yesterday, Allen Lutz from Bank of America Securities maintained a Sell rating on Hims & Hers Health, with a price target of $13.00. The company’s shares closed last Monday at $15.51, close to its 52-week low of $11.20.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
Hims & Hers Health has an analyst consensus of Hold, with a price target consensus of $32.03, implying a 102.8% upside from current levels. In a report issued on February 9, Citi also maintained a Sell rating on the stock with a $16.50 price target.
